Compare NTB & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTB | TWST |
|---|---|---|
| Founded | 1858 | 2013 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2016 | 2018 |
| Metric | NTB | TWST |
|---|---|---|
| Price | $51.96 | $31.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $50.67 | $44.88 |
| AVG Volume (30 Days) | 159.4K | ★ 1.4M |
| Earning Date | 10-28-2025 | 02-02-2026 |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | ★ 17.07 | N/A |
| EPS | ★ 5.27 | N/A |
| Revenue | ★ $599,452,000.00 | $376,572,000.00 |
| Revenue This Year | $4.46 | $15.19 |
| Revenue Next Year | N/A | $15.10 |
| P/E Ratio | $9.75 | ★ N/A |
| Revenue Growth | 4.60 | ★ 20.32 |
| 52 Week Low | $34.77 | $23.30 |
| 52 Week High | $51.83 | $55.33 |
| Indicator | NTB | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 82.82 | 54.42 |
| Support Level | $50.80 | $30.21 |
| Resistance Level | $51.83 | $33.31 |
| Average True Range (ATR) | 0.91 | 1.81 |
| MACD | 0.22 | 0.07 |
| Stochastic Oscillator | 95.06 | 62.68 |
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It operates the business through three geographic segments, Bermuda, Cayman Islands, the Channel Islands and the UK. The company offers banking services, comprised of retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. The company generates a majority of its revenue from Bermuda, and the Cayman Islands segments.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.